First AD

Second AD

Myeloproliferative Neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Current and Future Trends in Myeloproliferative Neoplasms

Peer Exchange

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

Management of Accelerated Phase Myeloproliferative Neoplasms

Myeloproliferative Neoplasms: Essential Thrombocythemia

Managing Patients with Essential Thrombocythemia

Myeloproliferative Neoplasms: Polycythemia Vera

Treatment Options for Polycythemia Vera

PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

Myeloproliferative Neoplasms: Myelofibrosis

Risk Stratification for Myelofibrosis

Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

New JAK Inhibitors in Myelofibrosis Treatment

Efficacy and Safety of JAK Inhibitors for Myelofibrosis

Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

Novel Agents Under Investigation for Myelofibrosis

Clinical Scenario: A 67-Year-Old with Myelofibrosis

Myelofibrosis Treatment Approaches after Disease Progression

Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

The Future of Myeloproliferative Neoplasm Treatment